Objective: The purpose of the present study was to collect data from population-based cancer registries and to calculate relative 5-year survival of cancer patients in Japan. We also sought to determine time trends and to compare the results with international studies. Methods: We asked 11 population-based cancer registries to submit individual data for patients diagnosed from 1993 to 1999, together with data on outcome after 5 years. Although all these registries submitted data (491 772 cases), only six met the required standards for the quality of registration data and follow-up investigation. The relative 5-year survival calculated by pooling data from 151 061 cases from six registries was taken as the survival for cancer patients in Japan. Results: Relative 5-year survival (1997 -99) was 54.3% for all cancers (males: 50.0%, females: 59.8%). Survival figures for all sites changed slightly over the 7-year period, from 53.2% for the first 4 years of the study (1993 -96) to 54.3% for the last 3 years (1997 -99), however, a major improvement was observed in several primary sites. Some overall survival was lower in Japan than in the USA, but similar to that in European countries. Specifically, survival for uterine cancer, prostate cancer, testis cancer, lymphoma and leukemia was much lower in Japan than in other countries. However, survival was better in Japan mainly for cancers of the esophagus, stomach, colon, liver and gallbladder. Conclusion: The study suggests an improvement in cancer survival in several primary sites in Japan, which is consistent with the development of treatments and early detection.
INTRODUCTION
Cancer survival, as assessed based on population-based cancer registries, is a valuable medical indicator to evaluate the progress of cancer control in a country or region. Precise population-based cancer survival is a comprehensive, practical and timely index for cancer control in a country. Use of relative 5-year survival statistics is useful to evaluate therapeutic effect in cancer incidence/mortality trends in real time. Cancer survival has also been shown to be powerful when comparing survival between sex, age groups and socioeconomic groups or between geographic areas where incidence or death due to other causes may differ.
However, this information is not often available because of legislative, financial and technical difficulties in following-up patients, even in population-based cancer registries in developed nations.
Clinical research groups frequently publish hospital-based survival rates for cancer patients at specific medical facilities (1 -3) ; however, these data do not provide useful information to political planners because of inevitable recruitment bias. Population-based survival is a thus prerequisite for designing public health projects and evaluating the efficacy of cancer prevention, screening and treatment.
In 1998, we proposed standard methods which required checking of vital status of patients by inquiring to the resident registration 5 years after diagnosis (4) . We reported relative 5-year survival based on these methods for stomach, lung and breast cancer diagnosed from 1985 to 1989, using data from cancer registries of Yamagata, Fukui and Osaka Prefectures (5) , which had collected data satisfying the methodological criteria. In 2001, we collected, from 12 registries belonging to the study group, individual data from all cancer patients (for all sites) diagnosed in 1993 for whom outcome information after 5 years was available. From this data we attempted to produce a nationwide relative 5-year survival according to standard methods (6) . This nationwide survival, however, could not be completed because there were differences in the quality of registration and assessment methods of outcome among the 12 registries. A population-based survival was therefore not published in Japan until 2006 (7) . This first population-based study reported that relative 5-year survival calculated by pooling 279 000 data from 7 registries was 49.2% for males and 59.4% for females.
The aims of the study were first to calculate the most recent relative 5-year survival of cancer patients in Japan, and second to observe changes in survival by comparing the data between two observation periods, 1993 -96 and 1997-99, and by comparison with the results of international studies.
PATIENTS AND METHODS
Eleven among 15 registries (Miyagi, Yamagata, Niigata, Chiba, Kanagawa, Fukui, Aichi, Shiga, Osaka, Tottori, Okayama, Saga, Nagasaki, Kumamoto and Okinawa) submitted individual data (a total of 491 772 cases) to the survival study. These 15 registries were selected because they had relatively high-quality data tracing the 5-year outcome of patients diagnosed from 1993 to 1999. They had also participated in the Monitoring of Cancer Incidence in Japan (MCIJ) project for 2002 incident cases (8) . We requested 11 population-based cancer registries to submit patient data for cancers at all sites, diagnosed from 1993 to 1999, including information on outcome after 5 years. We pooled cancer registry data that met standards of data quality in terms of both registration and outcome assessment.
QUALITY CRITERIA FOR AREA SELECTION
The quality criteria were based on the standards adopted in the above-mentioned MCIJ project: DCO% (death certificate only: proportion of patients for whom the death certificate provides the only notification to the registry) ,25% or DCN% (death certificate notification: proportion of patients for whom the death certificate provides the first notification to the registry) ,30%, and IM ratio (incidence to mortality ratio) less than 1.5 (8) . Among the 11 registries, six (Miyagi, Yamagata, Niigata, Fukui, Osaka and Nagasaki) met the required standards for the quality of registration and outcome assessment. According to the data provided by these registries, we calculated survival rates and considered them to be a nationwide index.
As far as the quality of outcome assessment was concerned, we set two criteria relating to follow-up methods. For registries checking survival of patients by referring to resident registries (active follow-up; Yamagata, Fukui and Osaka), we specified that the proportion of outcome-unknown cases 5 years after diagnosis should be ,5%. For registries having no confirmation of survival 5 years after diagnosis ( passive follow-up; Miyagi, Niigata and Nagasaki), we specified that information on personal identification including names would be computerized in order to collate the registered patients with death information with high accuracy. Registries that met these criteria were therefore guaranteed to have sufficiently accurate information about death.
SURVIVAL CALCULATION
Referring to other studies, since 1996 the research group has set standardized methods of calculating survival in Japan through the collaborative study of population-based cancer registries. The method of calculating survival is mainly based on the EUROCARE study (9) . In concrete terms, we excluded DCO cases, cancers in situ and mucosal cancers of the large bowel from the analysis. In the case of multiple cancers, only the first-diagnosed tumor was analyzed.
This study calculated the survival for cancers including followed-back cases from DCN (Subjects 1) and excluding these cases (Subjects 2). The former method was that used in the EUROCARE study, and is suitable for international comparison of survival based on population-based cancer registries. The latter should instead be utilized for domestic comparison of survival in Japan where some registries do not conduct follow-back inquiries to medical institutions for DCN cases, according to death certificate information.
Survival for Subjects 2 is generally better than that for Subjects 1 because the latter include cases regarded as incident according to death information. Given the high proportion of incident cases not reported by medical facilities but registered on the basis of death certificates, the survival calculated for Subjects 1 may be underestimated. In contrast, it is also possible for survival to be overestimated in Subjects 2. In Japan, each population-based registry decides whether to apply active follow-up; consequently, the survival of Subjects 2 would be better than that of Subjects 1. In this study, we will regard the survival calculated for Subjects 2 as that of cancer patients in Japan.
Cumulative 5-year survivals were calculated starting from the date of diagnosis. Expected survivals were calculated using the cohort survival table based on life tables of the Japanese population and then using the survival probability in the general population similar to the patients in sex, birth year and age. The former were divided by the latter to obtain relative 5-year survivals.
If vital status was unknown at 5 years after diagnosis, cases were dealt with as alive at the last contact date (5). However, for the three registries that had not checked the survival of patients by referring to the resident registry, we regarded all cases whose death was not confirmed as being alive until 5 years, and survival was calculated on this basis.
RESULTS
SURVIVAL DATA QUALITY Table 1 shows the number of incident cases, validity indices of registration, and the number of study subjects for survival analysis, for each registry in the two studies. In 1997-99 there were 221 080 incident cases, and the following cases were excluded from the survival analysis: DCO (36 939 cases, 16.7% of the total), subsequent primary tumors (17 814 cases, 8.1% of the total), non-malignant tumors (565 cases, 0.3% of the total), and in situ cancers (3 264 cases, 1.5% of the total). In addition, after excluding patients with unknown age at diagnosis and those over 100 years old, we considered the rest (164 738 cases, 74.5% of the total) as Subjects 1. Moreover, for DCN cases, additional cancer reports were requested in Yamagata, Fukui and Osaka Prefectures, and the registry records of cases originating from death information were distinguished in Miyagi Prefecture. The number of cases in which we traced the death information to incidence was 13 677, 8.3% of the total. The number of final analysis subjects (Subjects 2) excluding these cases was 151 061, corresponding to 68.3% of the total. Table 2 shows the vital status at 5 years from diagnosis. In the Miyagi, Yamagata and Niigata Cancer Registries, in which the vital status of patients was checked after 5 years by referring to resident registries, the proportion of cases with unknown vital status was 2.0% among these three registries. Survival rate varied from 38.0 to 45.8%.
SURVIVAL BY AGE AND SEX Table 3 shows 5-year relative survival rate and standard error according to the primary site and sex, excluding the follow-back cases (i.e. in Subjects 2). The 5-year relative survival was 53.2% for all cancers diagnosed in 1993 -96 (M: 48.9%, F: 59.0%), while that for 1997 -99 was 54.3% (M: 50.0%, F: 59.8%).
When all sites were considered together, females had a higher survival than males (M: 50.0%, F: 59.8%). This tendency was evident for lip, oral cavity and pharynx (M: n % a n % a n % a n % a n % a n % The relative 5-year survivals for all sites decreased markedly in the elderly. In males, this difference was pronounced for cancers of the lip, oral cavity and pharynx, bladder and thyroid, as well as in malignant lymphoma and all leukemias. For women, there was a marked age-related decrease in survival for cancers of the lip, oral cavity and pharynx and uterus (cervix and corpus), as well as malignant lymphoma, multiple myeloma and all leukemias (Fig. 1) .
SURVIVAL AND TIME TRENDS FOR SURVIVAL BY PRIMARY SITE Survival probabilities for cancers of the cervix, prostate, larynx, bladder, corpus uteri, female breast, testis and thyroid ranged from 71.5 to 92.4%; those for ovary, mouth, oral cavity and pharynx, stomach, rectum and anus, and colon ranged from 52.0 to 68.9%; those for pancreas, gallbladder, liver, lung, multiple myeloma, esophagus, all leukemias and malignant lymphoma ranged from 6.7 to 49.9% (Table 3) .
Survival figures for all sites improved significantly over the 7-year period, increasing from 53.2% for the first observation period (1993 -96) to 54.3% in the second (1997 -99) ( Table 4 shows observed and relative 5-year survival by extent of disease at diagnosis. Relative survival for all sites 
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Cancer survival in Japan (1993-99) (C00 -C96) was 85.2% for localized tumors, 43.7% for those with regional lymph node or direct invasion to the adjacent tissue/organ and 10.1% for those with distant metastasis. When all sites were considered together, improvement in survival was found only for localized tumors; survival rate increased from 84.6 to 85.2% (P , 0.05). Among localized tumors, survival improvement between the two periods was observed for the esophagus, liver, lung and female breast; among tumors with regional lymph node or direct invasion to the adjacent tissue/organ, improvement was seen for the pancreas, lung, prostate and testis. No improvement was observed in distant metastatic tumor cases.
In contrast, survival deteriorated significantly between the two observation periods for localized bladder cancer, laryngeal cancer with regional lymph node or adjacent organ metastasis, and gallbladder cancer with distant metastasis. Table 5 shows relative 5-year survivals in the current study, SEER study (10) and EUROCARE4 study (11) . Compared with the American data (SEER study), overall all-age survival was lower in Japan (64.9 -54.3%); however, age-standardized survival in Japan was similar to that in European countries (53.3 -51.9%). In particular, the survivals for Japanese patients with uterine cancer, prostate cancer, testicular cancer, lymphoma and leukemia were much lower than for their American counterparts. Survival in Japan was better than in Europe or the USA mainly for cancers of the digestive and hepatobiliary organs, such as the esophagus, stomach, colon, liver and gallbladder.
COMPARISON WITH INTERNATIONAL DATA

DISCUSSION
SURVIVAL IN JAPAN
On the basis of the data from six population-based cancer registries in Japan that met standards for data quality in terms of both registration and outcome assessment, we calculated the latest relative 5-year survival for major cancers.
Age differences were observed in survival when all sites were considered together and in some specific primary sites. Ioka et al. (12) found that advanced cervical cancers leading to poor survival are common in older people. Otherwise, this may be explained by histological differences or simply physical decline in older patients. Farley et al. (13) reported a similar decreasing survival with age in their study of uterine cancer. Studies of leukemia (14) and bladder cancer (15) also show similar effects of age.
Sex differences in survival for cancers at two primary sites, the larynx and lung, might be caused by biological differences between the two sexes and diagnostic circumstances. These differences could relate to smoking behavior in the two sexes, even for cancers of the same histology. Nordquist et al. (16) found differences in survival according to the smoking status of patients with adenocarcinoma of the lung. Another study showed that the survival of bladder cancer patients varies according to current smoking, age and gender, in addition to a latent promoter hypermethylation (17) . Bladder cancer is often at a more advanced tumor stage at diagnosis in women than in men.
COMPARISON BETWEEN THE TWO PERIODS AND WITH THE RESULTS OF INTERNATIONAL STUDIES
Overall chronological improvement of survival in several primary sites was observed, confirming the findings of a Improved significantly between the two observation periods **P , 0.01, *P , 0.05.
regional study (18) . Unfortunately, no change was seen in survival of cancers with distant metastases. There were particularly marked improvements in survival for cancers of the esophagus, liver and female breast, which might be mainly due to diffusion of organized screening programs in the society or development of early detection systems in cases of opportunistic screening (19 -22) . Treatment has also evolved during these two observational periods. Yamanaka et al. (23) reported, for example, that the establishment of indication criteria for hepatectomy and the 
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Cancer survival in Japan (1993-99) Continued introduction of multimodal treatment for recurrence were contributory factors. Lung cancer patients, particularly those with early stage disease, also benefit from improvements in surgical technique (24) . The increase in breast cancer survival likely results from development of new treatments. The breast conserving treatment with or without axillary dissection has been developed and replaced Halsted radical mastectomy in early 1990s in Japan. At the same time, endocrine therapy has progressed remarkably with acceptance of tamoxifen use in 1981. Since then LHRH agonist and aromatase inhibitors were approved one after another in the mid-1990s, and effective chemotherapy regimens in premenopausal women have also been developed: the majority of the university hospitals and clinics employed these new treatment strategies. We have to be cautious when considering prostate cancer survival because the early detection of micro tumors by PSA screening has been evident for more than a decade. However, considering that survival was particularly improved for cases with metastasis to regional lymph nodes or adjacent organs, the introduction of more effective radiation therapy might have contributed to the survival of older patients with prostate cancer (25) . We found that the overall survival of cancer patients in Japan is comparable with that in Europe (51.9%), although survival for some cancer types, particularly prostate cancer, lymphoma and leukemia, is much lower than in these Western countries. In contrast, the overall survival in the USA was much higher than Japan. This is probably due to the large difference of weights on breast and prostate cancer in cancer incidence. Survival for digestive organ and hepatobiliary cancers was better in Japan than in Western countries. For specific types of cancer, greater survival in a particular country tends to be correlated with higher incidence in that country (8) . A high survival rate might result from greater surgical volume for these primary sites (26) . In other words, compared with their Western counterparts, Japanese oncologists are usually more aware of digestive organ and hepatobiliary cancers and have greater experience in treatment of these cancers. Conversely, tumors that are sensitive to chemotherapy seem to be treated less effectively by Japanese oncologists. This slow progress in chemo-sensitive malignancies may demonstrate weaknesses of the system of oncology in Japan; serious shortage of oncologists specialized in chemotherapy and less centralized primary cancer treatment.
Changes over time in Japan were similar to those in the international studies examined. For example, considering changes in lung cancer and breast cancer, the time trends identified in Japan were very similar to those seen when comparing EUROCARE 3 and EUROCARE 4 (27) .
LIMITATIONS
To perform survival analyses in Japan, it is a priority to improve the quality of cancer registry data, because the high proportion of patients not registered will diminish the accuracy of survival estimates according to international criteria (28) . In this study, we required each registry to meet the necessary standards for participating in nationwide estimates of incidence (8) . It would be reasonable to assume, therefore, that the current study has been conducted on the basis of fairly accurate data from population-based cancer registries.
In the three prefectures where the vital status of patients was checked after 5 years from diagnosis, the proportion of unknown cases for vital status was only 2%, which implies that the assessment of outcome was highly accurate. The other three prefectures did not have the resources to check the vital status of patients in the resident registry. Table 2 shows that the survival proportion from these three registries was higher than that from the other three referring resident registries. The best way to collect more accurate survival All
improved significantly between the two observation periods **P , 0.01, *P , 0.05. deteriorated significantly between the two observation periods ** P , 0.01, * P , 0.05.
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Cancer survival in Japan data are to assess patient outcome by referring to resident registries. However, the fact that these registries do not check the survival of patients appears to have a modest effect on the overestimation of survival, because death information is very precise in Japan, and collation could be done with high accuracy in these three prefectures. Further, the frequency of patients moving to different prefectures is considered to be relatively low. Mucosal cancers of the large bowel should have been excluded from the survival analysis, since they are regarded as in situ cancers according to the agreement of the International Union Against Cancer (UICC) (29) . However, some population-based cancer registries in Japan still do not distinguish them. In this study, it seems that the proportions of mucosal cancer of the large bowel and of multiple primary cancers (except the first-diagnosed tumor) were negligible; it is therefore reasonable to think that they did not greatly affect survival results.
FUTURE OF SURVIVAL ANALYSIS IN JAPAN
The EUROCARE study is one of the most important collaborative studies of the European Union (9), currently involving 67 population-based cancer registries operating in 22 European countries (11) . Furthermore, the CONCORD study extends the EUROCARE study to include North America (31) , in addition, a similar international project on survival is ongoing in the Asia region; an Asian cancer registry network is being formed (32) . We confirmed the importance of calculating a comparable population-based survival as a measure of cancer control programs through the present study. Comparing the data chronologically and internationally, we figured out current situation, progress and international position of cancer screening and treatments in Japan. Drawing up a project or evaluating outcomes based on such a useful index is undoubtedly the basic principle of cancer control. Currently, it is highly recommended to analyze incidence, mortality and survival together in order to more fully understand the characteristics of cancer in a country (27, 33) . The Japanese research group is also conducting the MCIJ to monitor incidence, mortality and survival as the index of the progress of the cancer control routinely in Japan (34), and we hope to show the results to the world in the near future.
CONCLUSION
The study suggests an improvement in cancer survival in Japan in several primary sites during a relatively short period, which is consistent with the development of treatments and early detection. We confirmed that the overall survival of cancer patients in Japan is comparable with that in Europe. In contrast, the overall survival in the USA was much higher than Japan, but this is probably due to the difference of cancer incidence proportion.
